This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
The Proteomics Core Unit of the Spanish National Cancer Research Centre (CNIO), led by Javier Muñoz, has joined the European Proteomics Initiative Consortium (EPIC-XS), awarded with 10 million euro by the European Union to facilitate the development and sustainability of proteomics exploration to all life science researchers within the European Union.
Eighteen European research groups in the field of mass spectrometry based proteomics research throughout Europe participate in EPIC-XS, funded as part of the Horizon 2020 Work programme and coordinated by Albert Heck, professor of biomolecular mass spectrometry and proteomics at Utrecht University. The project, started on January and will run for a period of four years.
“The creation of this European consortium will allow us to open the doors of cutting-edge technology in proteomics to the scientific community”, says Muñoz. “The impact of this interaction will be high, allowing us to study and understand complex molecular processes involved in cancer and other diseases.”
Proteomics, the large-scale study of proteins and their role in living cells and organisms, is an important technology used to gain insight into the function of biological systems and the roles they play in health and disease. Mass spectrometry based proteomics requires state of the art technology, in-house technical know-how, sustainable and robust workflow practices, successful and correct data interpretation, and data management. Therefore, researchers often depend on dedicated proteomics facilities to get access to proteomics technology.
The EPIC-XS initiative will support researchers, by providing them with access to state of the art proteomics equipment, and allowing them to submit research proposals that make use of the proteomics technology offered by the project. All submitted proposals will be peer-reviewed and the best projects will be selected for access to EPIC-XS. This initiative is a follow-up of the previous European proteomics infrastructure project PRIME-XS, which was completed in 2015. EPIC-XS will again provide access to proteomics facilities throughout Europe, supporting and expanding the European proteomics community through its expertise in proteomics. The provision of courses and training programs, will enable new research communities to be schooled in advanced proteomics technologies.
The EPIC-XS consortium consists of partners throughout Europe which have a proven track record in facilitating national and international research within their institutions. All partners share a common goal; to facilitate the development and sustainability of proteomics exploration to all life science researchers within the European Union.
Starting in the spring of 2019, requests for access to the facilities can be submitted via www.epic-xs.eu.